Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - prochlorperazine maleate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; purified water; colloidal anhydrous silica; magnesium stearate - nausea and vomiting due to various causes including migraine; vertigo due to meniere's syndrome, labyrinthitis and other causes.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; lactose monohydrate; pregelatinised maize starch; sodium stearylfumarate; croscarmellose sodium - treatment of hypertension. data are currently not available to support the use of tryzan tabs in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium stearylfumarate; pregelatinised maize starch; sodium bicarbonate; croscarmellose sodium; iron oxide yellow; iron oxide red - treatment of hypertension. data are currently not available to support the use of tryzan tabs in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; sodium bicarbonate; croscarmellose sodium; lactose monohydrate; iron oxide yellow - treatment of hypertension. data are currently not available to support the use of tryzan tabs in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; pregelatinised maize starch; croscarmellose sodium; lactose monohydrate; sodium stearylfumarate - treatment of hypertension. data are currently not available to support the use of tryzan tabs in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diltiazem hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hydrogenated castor oil; aluminium hydroxide; methacrylic acid copolymer; purified talc; magnesium stearate; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - moderate to severe angina pectoris due to atherosclerotic coronary artery disease or coronary artery spasm (vasospastic angina).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - prochlorperazine maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; wheat starch; calcium hydrogen phosphate dihydrate; sodium lauryl sulfate - nausea and vomiting due to various causes including migraine; vertigo due to meniere's syndrome, labyrinthitis and other causes.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 180 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; sodium alginate; povidone; magnesium stearate; hypromellose; macrogol 400; macrogol 6000; purified talc; glycol/butylene glycol montanate; titanium dioxide; iron oxide red - cordilox sr (verapamil hydrochloride) is indicated for the management of hypertension and angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 450 mg - tablet, modified release - excipient ingredients: povidone; maize starch; gelatin; titanium dioxide; magnesium stearate; macrogol 6000; carmellose calcium; lactose monohydrate; calcium behenate; purified talc; basic butylated methacrylate copolymer - lithium is indicated in the treatment of acute episodes of mania and hypomania and for the prophylaxis of recurrent manic-depressive illness.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - prochlorperazine maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium lauryl sulfate; calcium hydrogen phosphate dihydrate; wheat starch; magnesium stearate - nausea and vomiting due to various causes including migraine; vertigo due to meniere's syndrome, labyrinthitis and other causes.